Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Serial immunomonitoring of cancer patients receiving combined antagonistic anti-CD40 and chemotherapy reveals consistent and cyclical modulation of T cell and dendritic cell parameters

Fig. 1

a Patient treatment schedule showing timings of study drug administration and PBMC collection; Chemo = pemetrexed/cisplatin chemotherapy, CP = CP-870,893. Blood was collected at baseline, then days 1, 8 and 15 of each treatment cycle for a maximum of 6 cycles combined therapy. b Representative flow cytometry data demonstrating gating strategy for DC. Forward scatter (FSC) area vs. FSC-height was used for doublet discrimination. A ‘dump’ channel was used to gate out dead cells (LIVE/DEAD viability stain) plus those staining positively with a CD3/CD14/CD16/CD19/CD56 lineage cocktail (lin+). DCs were identified as linHLA-DR+ cells, and respective DC subpopulations identified by BDCA-1, BDCA-2 or BDCA-3. c Longitudinal flow cytometry data on DC across six cycles of chemoimmunotherapy, for BDCA-1, BDCA-2 and BDCA-3 subpopulations as a proportion of total PBMC. Left-hand panels show observed values from individual patients, together with their empirical means (solid line), mean and SD at baseline are quoted. Centre panels show results of fitting a linear mixed model; a linear trend over time and additive treatment effects of the day of the treatment yield the corresponding population average curves. Black and white numbered bars on X-axes represent the number of treatment cycles undertaken, time point ‘B’ represent pre-study baseline samples. Y axis scales have been modified from left-hand panels for clarity to show cyclical changes highlighted by modelling. Average change over the duration of the study is described. Right-hand panels show estimated treatment means, showing differences between day 1, day 8, and day 15 of the chemoimmunotherapy treatment over 6 cycles (P-values: * <0.05, ** <0.01, *** <0.001, **** < 0.0001). d Longitudinal data on the ratio of BDCA-1 to BDCA-2 dendritic cells

Back to article page